Global CAR-T Cell Therapy Market
Global CAR-T Cell Therapy Market Expected to Surge to USD 34.04 Billion by 2034 with a CAGR of 23.33%
March 27, 2024 08:50 ET | Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
logo-header-min.png
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
March 25, 2024 17:45 ET | Marker Therapeutics
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...
logo-header-min.png
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 22, 2024 12:30 ET | Marker Therapeutics
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Turnstone Logo.jpg
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
March 21, 2024 17:06 ET | Turnstone Biologics Corp.
Turnstone reports fourth quarter and full year 2023 financial results and provides recent business highlights.
SentiBioLogo.jpg
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
March 21, 2024 16:05 ET | Senti Biosciences, Inc.
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...
Immatics Final logo (R)_white_background.png
Immatics Announces Full Year 2023 Financial Results and Corporate Update
March 21, 2024 07:00 ET | https://immatics.com/
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024 16:05 ET | Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 16:00 ET | Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Global Regenerative Medicine Market
Regenerative Medicine Industry Analysis and Outlook 2024-2034: Oncology Applications Lead the Forecasted $168 Billion Global Market
March 11, 2024 13:40 ET | Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Regenerative Medicine Market Analysis & Forecast to 2024-2034: Market By Product; By Application; By End-user; and By Region" report has...
22157.jpg
Cell Therapy Market Insights Report: Collaboration and Licensing Deals 2016-2023
March 11, 2024 13:31 ET | Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Cell Therapy Collaboration and...